EUCTR2012-001700-37-DK进行中（未招募）1 期
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure - CUPID Phase 2b Trial
Celladon Corporation0 个研究点目标入组 250 人开始时间: 2012年10月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Negative neutralizing AAV1 antibodies (NAb) (titer <1:2 or equivocal) within 90 days of screening.
- •2. 18-80 years of age, inclusive, at the time of signing the informed consent.
- •3. Chronic systolic HF due to ischemic or non-ischemic cardiomyopathy. Subjects with ischemic cardiomyopathy must have at least one major coronary vessel with TIMI grade 3 flow. If a subject has not undergone coronary angiography within 2 months, this criterion may be assessed after the subject is randomized and undergoes angiography just prior to the planned infusion of IMP.
- •a. Hypertrophic cardiomyopathy is excluded.
- •b. Toxic and alcoholic cardiomyopathies are allowed as long as toxin or alcohol exposure has been eliminated and a sufficient amount of time has elapsed to rule-out spontaneous recovery.
- •4. Left ventricular ejection fraction (LVEF) =35% anytime during the 60-day window prior to administration of IMP.
- •5. Diagnosis of NYHA class II, III or IV heart failure for a minimum of 90 days prior to screening.
- •6. Individualized, maximal, optimized HF therapy consistent with American College of Cardiology/American Heart Association and European Society of Cardiology practice guidelines for the treatment of chronic heart failure(ACC/AHA/ESC HF guidelines) and as updated from time to time:
- •a.Medical therapy as appropriate to the individual subject including oral diuretic, angiotensin-converting enzyme (ACE) inhibitor (or angiotensin-receptor blocker (ARB) if ACE intolerant) and, as tolerated, beta blocker at approved dosages as labeled in the respective package insert. The choice of beta blocker is limited to those approved for heart failure in all participating countries (bisoprolol, carvedilol or sustained release metoprolol succinate). Unless contraindicated or not tolerated, the addition of an aldosterone antagonist should be considered in the absence of hyperkalemia and significant renal dysfunction and according to evolving standards; the final decision is at the discretion of the investigator. Dosing of the above medications must be stable for a minimum of 30 days prior to screening, although up- or down-titration of diuretics, as medically indicated, is permitted. Enrollment of any subject with any deviation from this combination must be preapproved by the medical monitor.
- •b. Resynchronization therapy, if clinically indicated according to ACC/AHA/ESC HF guidelines, must have been implanted at least 6 months prior to screening.
- •c. Implantable cardioverter defibrillator (ICD), if clinically indicated according to ACC/AHA/ESC HF guidelines, must have been implanted a minimum of 30 days prior to screening.
- •d. Cardiac rehabilitation should be consistent with the Agency for Health Care Policy and Research Clinical Practice Guideline, Number 17, Cardiac Rehabilitation. This does not imply that the potential candidate must be enrolled in a cardiac rehabilitation program at screening or in the future.
- •7. All women of childbearing potential must have a negative urine pregnancy test prior to administration of IMP and agree to use adequate contraception (defined as oral or injectable contraceptives, intrauterine devices, surgical sterilization or a combination of a condom and spermicide) or limit sexual activity to vasectomized partner for 3 months after administration of IMP. Men capable of fathering a child must agree to use barrier contraception (combination of a condom and spermicide) or limit activity to post-menopausal, surgically sterilized, or a cont
排除标准
- •1.Any intravenous (IV) therapy with positive inotropes, vasodilators or diuretics within 30 days prior to screening.
- •2. Restrictive cardiomyopathy, obstructive cardiomyopathy, acute myocarditis, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease or discrete LV aneurysm.
- •3. Cardiac surgery, percutaneous coronary intervention (PCI) or valvuloplasty within 30 days prior to screening.
- •4. Myocardial infarction (e.g., ST elevation MI [STEMI] or large non-STEMI) within 90 days prior to screening. Large non-STEMI shall be defined >3x ULN for CK-MB or >5x ULN for troponin.
- •5. Prior heart transplantation, left ventricular reduction surgery (LVRS), cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device), surgically implanted LVAD or cardiac shunt.
- •6. Likely need for an immediate heart transplant or LVAD implant due to hemodynamic instability.
- •7. Prior CABG is not considered ideal for inclusion in the study; however, a potential candidate can be reviewed on a case-by-case basis. Ideally, the orifice of the graft should be easy to engage with a catheter and the graft should perfuse a significant amount of potentially viable myocardium.
- •8. Known hypersensitivity to contrast agents used for angiography; history of, or likely need for, high dose steroid pretreatment prior to contrast angiography.
- •9. Significant, in the opinion of the investigator, left main or ostial right coronary luminal stenosis.
- •10. Liver function tests (ALT, AST, alkaline phosphatase) >3x Upper Limit of Normal (ULN) within 30 days prior to IMP administration or known intrinsic liver disease (e.g., cirrhosis, chronic hepatitis B or hepatitis C virus infection).
- •11. Current or likely need for hemodialysis within 12 months following enrollment or current GFR =20 mL/minute/1.73 m2 estimated by MDRD calculation.
- •12. Bleeding diathesis or thrombocytopenia defined as platelet count <50,000 platelets/µL.
- •13. Anemia defined as hemoglobin <9 g/dL, provided that there is no evidence of bleeding.
- •14. Known AIDS or HIV seropositive status, or a previous diagnosis of immunodeficiency with an absolute neutrophil count <1000 cells/mm3.
- •15. Diagnosis of, or treatment for, any cancer other than basal cell carcinoma within the last 5 years. (Past medical history of cancer is not exclusionary as long as subject has been disease-free for at least 5 years since the time of diagnosis and treatment).
- •16. Previous participation in a study of gene transfer; however, if the study was unblinded or documentation otherwise exists that the subject was randomized to the placebo control group and did not receive active gene transfer agent, the subject may be considered for this study.
- •17. Receiving investigational intervention or participating in another clinical study within 30 days or within 5 half-lives of the investigational drug administration prior to screening. Exception may be made if the individual is enrolled in a non-therapeutic observational study (registry) or the observational portion of a therapeutic study where the sponsoring authority authorizes enrollment.
- •18. Pregnant or breast-feeding.
- •19. Recent history of psychiatric disease, including drug or alcohol abuse, that is likely to impair, in the opinion of the investigator, the subject’s ability to comply with protocol-mandated procedures.
- •20. Other concurrent medical condition(s) that, while not explicitly excluded by the protocol, could jeopardize the safety of the subject or ob
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of IntracoronaryAdministration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart FailureEUCTR2012-001700-37-HUCelladon Corporation250
进行中（未招募）
不适用
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart FailureModerate to advanced heart failure (NYHA class II, III or IV) due to systolic dysfunctionMedDRA version: 18.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849EUCTR2012-001700-37-PLCelladon Corporation250
进行中（未招募）
不适用
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart FailureModerate to advanced heart failure (NYHA class II, III or IV) due to systolic dysfunctionMedDRA version: 18.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849EUCTR2012-001700-37-BECelladon Corporation250
进行中（未招募）
1 期
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart FailureMedDRA version: 19.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849Moderate to advanced heart failure (NYHA class II, III or IV) due to systolic dysfunctionEUCTR2012-001700-37-DECelladon Corporation250
进行中（未招募）
1 期
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart FailureModerate to advanced heart failure (NYHA class III/IV) due to systolic dysfunctionMedDRA version: 15.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2012-001700-37-NLCelladon Corporation250